Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)

Business: Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

IPO Date: 30-Nov-2005

Pres, CEO & Exec. Director: Mr. Spiro George Rombotis

Exec. VP of Fin., CFO, COO, Sec. & Exec. Director: Mr. Paul McBarron

Listing: NASDAQ: CYCCP

Country: United States

Headquarters: Berkeley Heights, NJ

Website: https://www.cyclacel.com

Market cap: $12.87 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.72 Mln

Cash: $29.64 Mln

Total Debt: $0.02 Mln

Insider's Holding: 0.48%

Liquidity: Low

52 Week range: $5.17 - 10.56

Shares outstanding: 12,497,400

10 Years Aggregate:

• CFO: $-123.59 Mln
• EBITDA: $-130.98 Mln
• Net Profit: $-118.78 Mln